Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Animal and cell studiesStub

P21

CNTF-derived peptide (P021)

A small peptide derived from ciliary neurotrophic factor, studied in mouse models of Alzheimer's disease.

Reconstitution calculator

At a glance

Animal and cell studies

The published evidence is from animals and cells. Little or nothing is published from controlled trials in people.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals: P21

    Laboratory and animal work. An animal result is not a result in people.

15
papers on PubMed
5
of them in people
0
randomized trials
3
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on P21 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of P21; no amount here is a recommendation.

P21: on PubMed

What PubMed held for P21 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

15
papers
5
in humans
0
clinical trials
0
randomized trials
2012: 0 papers122013: 0 papers2014: 2 papers142015: 1 papers2016: 1 papers162017: 3 papers2018: 0 papers182019: 1 papers2020: 1 papers202021: 1 papers2022: 1 papers222023: 1 papers2024: 1 papers242025: 0 papers2026: 2 papers so far26
Papers per year, 2012 to 2026. The most in one year: 3.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound

    StudyKhatoon S, Chalbot S, Bolognin S, et al. Journal of Alzheimer's disease : JAD, 2015. PMID 26401692

  2. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies

    ReviewLozupone M, Dibello V, Sardone R, et al. Expert opinion on drug discovery, 2023. PMID 37042028

  3. Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound

    ReviewBaazaoui N, Iqbal K Biomolecules, 2022. PMID 36291618

  4. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice

    StudyWei W, Wang Y, Liu Y, et al. Alzheimer's research & therapy, 2020. PMID 32854771

  5. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound

    StudyBolognin S, Buffelli M, Puoliväli J, et al. Neurobiology of aging, 2014. PMID 24702821

  6. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

    StudyBaazaoui N, Iqbal K Alzheimer's research & therapy, 2017. PMID 28655344

Search used: ("P021"[tiab] AND (neurogenesis[tiab] OR CNTF[tiab] OR Alzheimer[tiab])). Run it on PubMed

Research links

Also in Cognitive